Triple Therapy for Poorly Controlled Type 2 Diabetes: Metformin, SGLT-2i, GLP-1RA
Background
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by high blood sugar levels, often leading to severe complications like heart disease, kidney failure, and nerve damage. Despite numerous available treatments, many patients still struggle with poor glycemic control, necessitating more effective combination therapies. This Phase 4 clinical trial aims to directly compare the efficacy and safety of a specific triple drug regimen (Metformin, SGLT-2i, GLP-1RA) against other established oral antidiabetic drug combinations in these challenging patients.
Study Design
This randomized, Phase 4 clinical trial, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., is currently recruiting an estimated 430 adult patients diagnosed with Type 2 Diabetes who exhibit poor glycemic control. Participants will be assigned to one of two treatment arms. The experimental arm will receive a triple combination of Metformin (at baseline dosage), ganagliflozin (50mg/d), and liraglutide (an injectable GLP-1 receptor agonist, titrated from 0.6 mg/d in week one to 1.8 mg/d after week three). The active comparator arm will continue Metformin (at baseline dosage) and add 1-2 other oral hypoglycemic agents (excluding SGLT-2 inhibitors and oral GLP-1 receptor agonists) to form their triple therapy. The study is projected to run from March 2025 to June 2028.
Results
As of the current status, this study (NCT ID: NCT07244003) is RECRUITING participants, meaning no efficacy or safety results have been reported yet. The primary objective is to evaluate the change in HbA1c (a key marker of long-term blood sugar control) from baseline in both treatment groups. Secondary outcomes will likely include changes in body weight, blood pressure, lipid profiles, and the incidence of adverse events, providing a comprehensive safety and tolerability assessment. The study aims to enroll an estimated 430 participants. The central goal of this Phase 4 trial is to determine if the specific combination of Metformin, ganagliflozin, and liraglutide leads to a significantly greater reduction in HbA1c compared to other triple oral antidiabetic drug regimens in patients with poor glycemic control.
Why It Matters
Optimizing treatment strategies for patients with Type 2 Diabetes and poor glycemic control is a critical unmet medical need, as uncontrolled blood sugar significantly increases the risk of severe complications. This Phase 4 study is designed to provide real-world evidence on the comparative effectiveness and safety of a potent triple therapy. If the Metformin + ganagliflozin + liraglutide combination proves superior, it could establish a new, highly effective standard of care for managing challenging cases of Type 2 Diabetes. The findings will directly inform clinical guidelines and treatment decisions, potentially improving patient outcomes on a broad scale.